Predictors for poor cosmetic outcome in patients with early stage breast cancer treated with breast conserving therapy: Results of the Young boost trial



      In the Young Boost trial (YBT), breast cancer patients ≤50 years of age, treated with breast conserving therapy (BCT) were randomized between a 26 Gy boost dose and a 16 Gy boost dose, with local recurrence as primary and cosmetic outcome (CO) as secondary endpoint. Data of the YBT was used to investigate which factors are related with worse cosmetic outcome after BCT.


      From 2004 to 2011, 2421 cT1-2N0-2a breast cancer patients were randomized. CO was scored subjectively by the patient and physician, and objectively using BCCT.core: at baseline, one and four years after treatment. Associations between potential risk factors for worse cosmetic outcome, based on the objective BCCT.core, were investigated using a proportional odds model.


      At four years, CO was significantly better in the standard boost group for all three scoring methods (satisfied CO ±65% vs 55%). A photon boost, high boost dose, poor cosmesis before radiation therapy, large boost volume and adjuvant chemotherapy significantly deteriorated CO.


      Important risk factors for worse CO were the use of a photon boost instead of an electron boost, a high boost dose, cosmesis at baseline, adjuvant chemotherapy and boost volume. These results can be used to define strategies aimed at improving CO.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Radiotherapy and Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Clarke M.
        • Collins R.
        • Darby S.
        • et al.
        Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials.
        Lancet. 2005; 366: 2087-2106
        • Poortmans P.M.
        • Collette L.
        • Bartelink H.
        • et al.
        The addition of a boost dose on the primary tumour bed after lumpectomy in breast conserving treatment for breast cancer. A summary of the results of EORTC 22881–10882 “boost versus no boost” trial.
        Cancer Radiother. 2008; 12: 565-570
        • Bartelink H.
        • Horiot J.-C.
        • Poortmans P.M.
        • et al.
        Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer: 10-year results of the randomized boost versus no boost EORTC 22881–10882 trial.
        J Clin Oncol. 2007; 25: 3259-3265
        • Barnett G.C.
        • Wilkinson J.S.
        • Moody A.M.
        • et al.
        The Cambridge Breast Intensity-modulated Radiotherapy Trial: patient- and treatment-related factors that influence late toxicity.
        Clin Oncol (R Coll Radiol). 2011; 23: 662-673
        • Peterson D.
        • Truong P.T.
        • Parpia S.
        • et al.
        Predictors of adverse cosmetic outcome in the RAPID trial: an exploratory analysis.
        Int J Radiat Oncol. 2015; 91: 968-976
      1. Vrieling C, Collette L, Fourquet A, et al., The influence of patient, tumor and treatment factors on the cosmetic results after breast-conserving therapy in the EORTC ‘boost vs . no boost’ trial, 2000.

        • Immink J.M.
        • Putter H.
        • Bartelink H.
        • et al.
        Long-term cosmetic changes after breast-conserving treatment of patients with stage I-II breast cancer and included in the EORTC “boost versus no boost” trial.
        Ann Oncol. 2012; 23: 2591-2598
        • Mukesh M.B.
        • Harris E.
        • Collette S.
        • et al.
        Normal tissue complication probability (NTCP) parameters for breast fibrosis: pooled results from two randomised trials.
        Radiother Oncol. 2013; 108: 293-298
        • Collette S.
        • Collette L.
        • Budiharto T.
        • et al.
        Predictors of the risk of fibrosis at 10 years after breast conserving therapy for early breast cancer: a study based on the EORTC Trial 22881–10882 “boost versus no boost”.
        Eur J Cancer. 2008; 44: 2587-2599
        • Vrieling C.
        • Collette L.
        • Fourquet A.
        • et al.
        The influence of the boost in breast-conserving therapy on cosmetic outcome in the EORTC “Boost versus no Boost” Trial.
        Int J Radiat Oncol. 1999; 45: 677-685
        • Hammer C.
        • Maduro J.H.
        • Bantema-Joppe E.J.
        • et al.
        Radiation-induced fibrosis in the boost area after three-dimensional conformal radiotherapy with a simultaneous integrated boost technique for early-stage breast cancer: A multivariable prediction model.
        Radiother Oncol. 2017; 122: 45-49
        • Brouwers P.J.A.M.
        • van Werkhoven E.
        • Bartelink H.
        • et al.
        Factors associated with patient-reported cosmetic outcome in the Young Boost Breast Trial.
        Radiother Oncol. 2016; 120: 107-113
      2. Sobin LH, Gospodarowicz MK WC. TNM classification of malignant tumors.; 2002.

        • Scott N.W.
        • McPherson G.C.
        • Ramsay C.R.
        • Campbell M.K.
        The method of minimization for allocation to clinical trials: a review.
        Control Clin Trials. 2002; 23: 662-674
        • Cardoso M.J.
        • Cardoso J.
        • Amaral N.
        • et al.
        Turning subjective into objective: the BCCT.core software for evaluation of cosmetic results in breast cancer conservative treatment.
        Breast. 2007; 16: 456-461
        • Cardoso J.S.
        • Cardoso M.J.
        Towards an intelligent medical system for the aesthetic evaluation of breast cancer conservative treatment.
        Artif Intell Med. 2007; 40: 115-126
        • Harris J.R.
        • Levene M.B.
        • Svensson G.
        • Hellman S.
        Analysis of cosmetic results following primary radiation therapy for stages I and II carcinoma of the breast.
        Int J Radiat Oncol. 1979; 5: 257-261
        • Sneeuw K.C.
        • Aaronson N.K.
        • Yarnold J.R.
        • et al.
        Cosmetic and functional outcomes of breast conserving treatment for early stage breast cancer. 1. Comparison of patients’ ratings, observers’ ratings, and objective assessments.
        Radiother Oncol. 1992; 25 ( 153-159
        • Al Uwini S.
        • Antonini N.
        • Poortmans P.M.
        • et al.
        The influence of the use of CT-planning on the irradiated boost volume in breast conserving treatment.
        Radiother Oncol. 2009; 93: 87-93
        • Mukesh M.B.
        • Barnett G.C.
        • Wilkinson J.S.
        • et al.
        Randomized controlled trial of intensity-modulated radiotherapy for early breast cancer: 5-year results confirm superior overall cosmesis.
        J Clin Oncol. 2013; 31: 4488-4495
        • Lazzari G.
        • Terlizzi A.
        • Della Vittoria Scarpati G.
        • et al.
        Predictive parameters in hypofractionated whole-breast 3D conformal radiotherapy according to the Ontario Canadian trial.
        Onco Targets Ther. 2017; 10: 1835-1842
        • Veldeman L.
        • Schiettecatte K.
        • De Sutter C.
        • et al.
        The 2-year cosmetic outcome of a randomized trial comparing prone and supine whole-breast irradiation in large-breasted women.
        Int J Radiat Oncol Biol Phys. 2016; 95: 1210-1217
        • Haviland J.S.
        • Owen J.R.
        • Dewar J.a.
        • et al.
        The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials.
        Lancet Oncol. 2013; 14: 1086-1094
        • Whelan T.J.
        • Pignol J.-P.
        • Levine M.N.
        • et al.
        Long-term results of hypofractionated radiation therapy for breast cancer.
        N Engl J Med. 2010; 362: 513-520
        • Bantema-Joppe E.J.
        • Schilstra C.
        • de Bock G.H.
        • et al.
        Simultaneous integrated boost irradiation after breast-conserving surgery: physician-rated toxicity and cosmetic outcome at 30 months’ follow-up.
        Int J Radiat Oncol Biol Phys. 2012; 83: e471-e477
        • Lansu J.T.P.
        • Essers M.
        • Voogd A.C.
        • et al.
        The influence of simultaneous integrated boost, hypofractionation and oncoplastic surgery on cosmetic outcome and PROMs after breast conserving therapy.
        Eur J Surg Oncol. 2015; 41: 1411-1416
        • Keller L.M.M.
        • Sopka D.M.
        • Li T.
        • et al.
        Five-year results of whole breast intensity modulated radiation therapy for the treatment of early stage breast cancer: The fox chase cancer center experience.
        Int J Radiat Oncol Biol Phys. 2012; 84: 881-887
        • Franco P.
        • Cante D.
        • Sciacero P.
        • Girelli G.
        • La Porta M.R.
        • Ricardi U.
        Tumor bed boost integration during whole breast radiotherapy: a review of the current evidence.
        Breast Care. 2015; 10: 44-49
        • González Sanchis A.
        • Brualla González L.
        • Fuster Diana C.
        • et al.
        Tumor bed segmentation: first step for partial breast irradiation.
        Clin Transl Oncol. 2013; 15: 39-45
        • Furet E.
        • Peurien D.
        • Fournier-Bidoz N.
        • et al.
        Plastic surgery for breast conservation therapy: how to define the volume of the tumor bed for the boost?.
        Eur J Surg Oncol. 2014; 40: 830-834
        • Boersma L.J.
        • Janssen T.
        • Elkhuizen P.H.M.
        • et al.
        Reducing interobserver variation of boost-CTV delineation in breast conserving radiation therapy using a pre-operative CT and delineation guidelines.
        Radiother Oncol. 2012; 103: 178-182
        • van der Heiden-van der Loo M.
        • Siesling S.
        • Wouters M.W.J.M.
        • van Dalen T.
        • Rutgers E.J.T.
        • Peeters P.H.M.
        The value of ipsilateral breast tumor recurrence as a quality indicator: hospital variation in the Netherlands.
        Ann Surg Oncol. 2015; 22: 522-528
        • Poortmans P.M.P.
        • Arenas M.
        • Livi L.
        Breast. 2017; 31: 295-302
        • Kirova Y.M.
        • Castro Pena P.
        • Hijal T.
        • et al.
        Improving the definition of tumor bed boost with the use of surgical clips and image registration in breast cancer patients.
        Int J Radiat Oncol Biol Phys. 2010; 78: 1352-1355